Robert J. Young

TL;DR: Dynamic susceptibility-weighted contrast material-enhanced perfusion MR imaging can be used to predict median time to progression in patients with gliomas, independent of pathologic findings.

TL;DR: It is shown that tumour-derived DNA was detected in CSF from 42 out of 85 patients (49.4%) and was associated with disease burden and adverse outcome and the ability to monitor the evolution of the glioma genome through a minimally invasive technique could advance the clinical development and use of genotype-directed therapies for gliomas.

TL;DR: This data demonstrates that with close imaging follow-up, radionecrosis after single-fraction SRS for brain metastases is not uncommon, and maximum tumor diameter on pre-treatment MR imaging can provide a reliable estimate of radionicrosis risk prior to treatment planning, with the greatest risk among tumors measuring >1 cm.

TL;DR: This review focuses on the need for QIBs in oncology applications and emphasizes the importance of the assessment of their reproducibility and repeatability.

TL;DR: No improvement in response was found and no evidence of an abscopal effect with the addition of SBRT to nivolumab in unselected patients with metastatic HNSCC.